Covalent Partners’s Bausch Health BHC Stock Holding History

Covalent Partners’s Portfolio BHC Stock Details BHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-40,000	Closed	-$324K	–	26
2023 Q1	$324K	Sell	40,000 -20,000	-33%	-$161K	0.72%	14
2022 Q4	$377K	Sell	60,000 -30,000	-33%	-$210K	0.43%	17
2022 Q3	$620K	Buy	+90,000	New	+$625K	0.88%	18

Other funds holding BHC

Icahn Carl Sunny Isles Beach, Florida $8.26B AUM 15.11% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Covalent Partners's BHC Position: Q2 2023 in Review

Covalent Partners sold out of Bausch Health (BHC) in Q2 2023, closing a stake of 40,000 shares — an estimated $324K sold.

Covalent Partners first reported a position in BHC in Q3 2022 and held it in 3 quarters. The position peaked at $620K in Q3 2022. 232 funds tracked by Wall St. Rank hold BHC as of Q2 2023.

Covalent Partners reported no remaining Bausch Health position as of Q2 2023 after selling out during the quarter.
Covalent Partners sold 40,000 Bausch Health shares in Q2 2023, an estimated $324K.
Covalent Partners first reported a position in Bausch Health in Q3 2022 and held it in 3 quarters.
Covalent Partners's Bausch Health position peaked at $620K in Q3 2022.
232 funds tracked by Wall St. Rank held Bausch Health as of Q2 2023.

Based on Covalent Partners's 13F filing for Q2 2023, filed 14 Aug 2023.